Prostate

Papers
(The H4-Index of Prostate is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
54
Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study48
Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy46
VOC‐based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine‐based approach40
Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level37
Erratum to “Inhibition of Signaling Downstream of Beta‐2 Adrenoceptor by Propranolol in Prostate Cancer Cells”27
Prognostic factors of overall and prostate‐specific antigen‐progression‐free survival in metastatic castration‐resistant prostate cancer patients treated with 177Lu‐PSMA‐617. A single‐cente24
The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer24
Impact of androgen receptor alterations on cell‐free DNA genomic profiling on survival outcomes in metastatic castration‐resistant prostate cancer24
Incidental Brain Metastases From Prostate Cancer Diagnosed With PSMA PET/CT and MRI: A Case Series and Literature Review24
23
3βHSD activity saturates at physiological substrate concentrations in intact cells23
Association of plasma NRP2 and VEGF‐C levels with prostate cancer disease severity22
A panel‐based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration‐resistant prostate cancer21
Investigation of pelvic floor influence on prostate displacement in image‐guided radiotherapy20
Real‐world study: Impact of multidisciplinary management of apalutamide‐associated adverse events in prostate cancer20
The effect of tranexamic acid on perioperative blood loss in transurethral resection of the prostate: A double‐blind, randomized controlled trial20
The 28th Annual Prostate Cancer Foundation Scientific Retreat report19
Chromogenic detection of telomere lengths in situ aids the identification of precancerous lesions in the prostate19
Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate‐resistant prostate cancer post‐abiraterone and/or enzalutamide19
Intermediate‐term oncological and functional outcomes of salvage cryotherapy for the management of prostate cancer recurrence after primary brachytherapy versus primary cryotherapy: A propensity score19
0.20564603805542